DuoTrav® Eye Drops As Replacement Therapy Program

This study has been completed.
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
First received: January 23, 2009
Last updated: September 18, 2012
Last verified: July 2012

To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).

Condition Intervention Phase
Open-angle Glaucoma
Ocular Hypertension
Drug: DuoTrav
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Intra Ocular Pressure [ Time Frame: visit 1, Visits 2-3, Visits 6-8 ] [ Designated as safety issue: No ]

Enrollment: 128
Study Start Date: February 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: DuoTrav
DuoTrav Eye Drops


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00828906

Contact Alcon for Trial Locations
Bejing, China
Sponsors and Collaborators
Alcon Research
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00828906     History of Changes
Other Study ID Numbers: DART-2
Study First Received: January 23, 2009
Last Updated: September 18, 2012
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Alcon Research:

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 15, 2014